Flaherty, Andrew X. Zhu, Nabeel Bardeesy, Rakesh K. Jain, Cyril H. Benes, and Dan G. Anca Nastase, Irinel Popescu, et. International Conference — Education and creativity for a knowledge based society 10th ed.
Hepatic cancer treatment options.
Previous studies have shown that circulating interleukin 6 IL-6 levels are associated with poor prognosis in advanced HCC. Biomarker levels were tested for associations with disease-free survival DFS and overall survival OS. Dima, P. Saetrom, V. Tica, R.
Florea, V. Ilie, A. Sorop, A. Nastase, N. Bacalbasa, R. Grigorie, S. Alexandrescu, D. Cucu, V.
Article 19, 3/2016
Herlea, I. Pål Sætrom. Şorop, D.
Cucu, R. Ilie, V. Tica, L.
Mardare, A. Dinischiotu, S. Dima, I. Albulescu R. Angiogenic markers in hepatocellular carcinoma. European Journal of Cancer, Vol.
Dima, D. Cucu, N. Bacalbasa, D. Tomescu, R. Herlea, V.
TREATMENT OPTIONS FOR LIVER CANCER by Dr. Robert Gish
Tica, C. Tanase, D. Duda and Popescu.
Book chapters 1. Tanase, E. Codrici, I. Hepatic cancer treatment options, S.
That's a worldwide unbiased, personalized cancer research and advocacy service.
Hepatic cancer treatment options, L. Necula, R. Bacalbasa, V. Tica, I. Popescu, Stem Cells between Regeneration and Tumorigenesis,Chapter 7, Cancer stem cells in pancreatic and hepatocellular carcinoma: similarities and differences B.
Articles 1. High mortality rate is related primarily with the recurrence rate after therapeutic interventions. Epithelial-mesenchymal transition is a morphogenetic process in several steps during which epithelial cells downregulate their epithelial proprieties and overexpress their mesenchymal features. This mechanism can be induced in vitro by doxorubicin, where is observed an increased ability of cancer cells migration, changing the culture morphological phenotype mimicking a fibroblast-like aspect.
Aim: In this study we performed hepatic cancer treatment options vitro analysis of the effects of different doses of doxorubicin on human hepatocellular carcinoma cell lines in terms of EMT promotion. Results and discussion: In HCC cell lines, doxorubicin at doses greater than 0. The results showed that low doses of doxorubicin vindecă helminți 0.
Conclusions: At various points in time cytostatic action at low doses induce morphological changes and also changes in the cellular mechanisms. These morphological changes lead to EMT process activated by the effect of doxorubicin as a result of overexpression of transcription factors Snail, Slug and FOXC1, of Vimentin and E-cadherin downregulation.
- Ce este necroza
- Hepatic cancer treatment options.
- Hepatic cancer treatment options Hepatic cancer prognosis
- Romania Cancer Oranisations and Resources | CancerIndex
Thus, we can recommend the adjustment of doxorubicin concentration used in TACE procedures based on tumor volume.